The S&P 500 has fallen roughly 5 percent from recent highs, prompting a rotation out of growth stocks into defensive names. For investors prioritizing income, Realty Income (O), Chevron (CVX), and Pfizer (PFE) offer compelling risk-adjusted returns backed by decades of dividend growth.
Realty Income trades at a 5.5 percent yield and distinguishes itself through monthly distributions—rare among dividend payers. The REIT's portfolio spans 96 industries with a 99 percent occupancy rate, reducing sector-specific risk. One-year total return of 6 percent reflects the equity's consolidation while the dividend compounds. Key catalysts: occupancy rate maintenance above 98 percent and sustained rent growth in its diversified tenant base signal durability through economic uncertainty.
Chevron offers a 3.4 percent yield—three times the S&P 500 average—backed by 35 percent upside over the trailing 12 months. The energy major raised its dividend for decades and benefits from structurally higher oil prices and inflation hedging. Watch: crude above $75 per barrel and free cash flow expansion from capex discipline to fund incremental payout increases.
Pfizer yields 5.9 percent, the highest of the three, but carries execution risk. The stock has underperformed by 40 percent over five years as COVID revenue collapsed and patent expirations loom. The pharmaceutical giant's moat—decades of drug development capability and market access—remains intact. Key catalyst: new drug approvals and revenue stability from its non-COVID pipeline justify the depressed valuation and high yield. Investors should monitor quarterly earnings for evidence of pipeline strength and margin recovery.
All three offer measurable downside protection during equity drawdowns, with yields substantially above risk-free rates, making them tactical additions to defensive positions.
